Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve RET -Mutant Medullary Thyroid Cancer

15 Aug 2022

Abstract excerpt

Selpercatinib is a first-in-class, highly selective and potent, central nervous system-active RET kinase inhibitor. In the phase I/II trial, selpercatinib demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pre-treated and treatment-naive patients with RET-mutant medullary thyroid cancer (MTC). LIBRETTO-531 (NCT04211337) is a multicenter, open-label, randomized, controlled,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Cancer-related Molecular Pathways
Share to Thyroid Cancer Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35969032
DOI: 10.2217/fon-2022-0657

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve RET -Mutant Medullary Thyroid CancerPMID 35969032Read ↗

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.Semantic proximity Read ↗

Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid CancerSemantic proximity Read ↗

Selpercatinib in the treatment of thyroid cancer.Semantic proximity Read ↗

Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.Semantic proximity Read ↗

Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RET.Semantic proximity Read ↗

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS MetastasesSemantic proximity Read ↗

RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.Semantic proximity Read ↗

Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET-Mutant Medullary Thyroid Cancer.Semantic proximity Read ↗

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions.Semantic proximity Read ↗

Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer.Semantic proximity Read ↗

Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectivesSemantic proximity Read ↗

Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.